Clinical trial
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal…
NCT00258297 · University of Rochester, Other · Terminated
Key facts
| NCT number | NCT00258297 |
|---|---|
| Title | Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery |
| Official title | A Phase II Safety, Efficacy, and Feasibility Study of Neoadjuvant ZD1839 (IRESSA) in Resectable Esophageal Cancer |
| Lead sponsor | University of Rochester, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Drug, Procedure |
| Interventions | gefitinib, conventional surgery, enzyme inhibitor therapy, neoadjuvant therapy, protein tyrosine kinase inhibitor therapy, surgery |
| Enrollment | 30 |
| Start date | Apr 1, 2004 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Nov 24, 2005 |
| Last update posted | Oct 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: